| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$32.14 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2019-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,844 |
17,263 |
|
- |
|
| Crane Rosemary A |
Director |
– • – |
2019-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,167 |
8,543 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-08-22 |
4 |
D |
$55.24 |
$230,682 |
D/D |
(4,176) |
46,427 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
11,261 |
50,603 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$54,626 |
D/D |
(954) |
39,342 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$126,258 |
D/D |
(2,205) |
53,332 |
|
- |
|
| Pravda Ricardo |
SVP, Human Resources |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$85,775 |
D/D |
(1,498) |
11,123 |
|
- |
|
| Arnold Jonathan |
President, Oral Drug Delivery |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$137,080 |
D/D |
(2,394) |
28,000 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$70,659 |
D/D |
(1,234) |
38,487 |
|
- |
|
| Maselli Alessandro |
President & COO |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$56,344 |
D/D |
(984) |
17,209 |
|
- |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$61,784 |
D/D |
(1,079) |
9,558 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$93,105 |
D/D |
(1,626) |
13,419 |
|
- |
|
| Hegwood Paul W Jr |
President, CSS |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$75,469 |
D/D |
(1,318) |
9,180 |
|
- |
|
| Gennadios Aristippos |
President, Softgel Tech. |
• – – |
2019-07-26 |
4 |
D |
$57.26 |
$42,830 |
D/D |
(748) |
35,617 |
|
- |
|
| Chiminski John R |
Chair & CEO |
• • – |
2019-07-26 |
4 |
D |
$57.26 |
$763,448 |
D/D |
(13,333) |
240,384 |
|
- |
|
| Pravda Ricardo |
SVP, Human Resources |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,238 |
12,621 |
|
- |
|
| Maselli Alessandro |
President & COO |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,549 |
18,193 |
|
- |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,002 |
10,637 |
|
- |
|
| Gennadios Aristippos |
President, Softgel Tech. |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,639 |
36,365 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,003 |
39,721 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,238 |
15,045 |
|
- |
|
| Hegwood Paul W Jr |
President, CSS |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
911 |
10,498 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,913 |
40,296 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,009 |
55,537 |
|
- |
|
| Arnold Jonathan |
President, Oral Drug Delivery |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,602 |
30,394 |
|
- |
|
821 Records found
|
|
Page 20 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (0.22%) 
